HC Wainwright Brokers Increase Earnings Estimates for NERV

Minerva Neurosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate for Minerva Neurosciences to a loss of $0.70 per share from a projected loss of $0.73; the consensus estimate was a loss of $0.73.
  • Minerva reported a quarterly loss of $1.60 per share, missing the consensus estimate of a $0.14 loss by $1.46.
  • Analyst sentiment was mixed: MarketBeat reported an average rating of Hold and an average price target of $10.33.
  • Five stocks to consider instead of Minerva Neurosciences.

Minerva Neurosciences, Inc (NASDAQ:NERV - Free Report) - Research analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Minerva Neurosciences in a research note issued to investors on Monday, November 9th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($0.70) per share for the year, up from their prior estimate of ($0.73). The consensus estimate for Minerva Neurosciences' current full-year earnings is ($0.73) per share.

Other analysts have also issued research reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Minerva Neurosciences in a research note on Monday, September 21st. Wall Street Zen cut shares of Minerva Neurosciences from a "hold" rating to a "sell" rating in a report on Saturday, October 31st. Jefferies Financial Group raised shares of Minerva Neurosciences from a "hold" rating to a "mixed" rating and lifted their target price for the stock from $7.50 to $10.00 in a research note on Friday, August 14th. Finally, Zacks Research upgraded shares of Minerva Neurosciences from a "strong sell" rating to a "hold" rating in a report on Friday, October 9th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $10.33.

Check Out Our Latest Research Report on NERV

Minerva Neurosciences Stock Down 1.8%

Shares of Minerva Neurosciences stock opened at $2.16 on Wednesday. Minerva Neurosciences has a one year low of $1.96 and a one year high of $8.80. The business's 50 day simple moving average is $2.92 and its two-hundred day simple moving average is $4.77.

Minerva Neurosciences (NASDAQ:NERV - Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($1.46).

Institutional Trading of Minerva Neurosciences

Several large investors have recently modified their holdings of the business. Janus Henderson Group PLC raised its position in Minerva Neurosciences by 47,614.0% during the 1st quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company's stock valued at $25,873,000 after purchasing an additional 4,285,259 shares during the last quarter. Seven Fleet Capital Management LP purchased a new stake in Minerva Neurosciences in the 1st quarter worth approximately $6,855,000. DV Trading LLC purchased a new stake in Minerva Neurosciences in the 1st quarter worth approximately $5,358,000. Bank of New York Mellon Corp purchased a new stake in Minerva Neurosciences in the 2nd quarter worth approximately $419,000. Finally, Bank of America Corp DE lifted its holdings in Minerva Neurosciences by 78,272.5% in the 1st quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company's stock worth $241,000 after buying an additional 39,919 shares during the period. 34.56% of the stock is owned by institutional investors.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. It focuses on developing treatments for central nervous system disorders and does not have marketed products. The company's principal drug candidate has been roluperidone, an oral medicine studied for negative symptoms of schizophrenia. The candidate remains investigational; its development has included clinical trials and regulatory review in the United States. Minerva's earlier research pipeline has also included MIN-301, a biologic candidate studied for Parkinson's disease.

Featured Stories

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Minerva Neurosciences Right Now?

Before you consider Minerva Neurosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Minerva Neurosciences wasn't on the list.

While Minerva Neurosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines